Jaguar Health Inc. has recently entered into a significant financial agreement involving a privately negotiated exchange with Iliad Research and Trading, L.P. The agreement, known as the Iliad Series M Exchange Agreement, was finalized on June 27, 2025. As part of this arrangement, Jaguar Health issued 170 shares of Series M Perpetual Preferred Stock to Iliad, resulting in a $4,250,000 reduction in the outstanding balance of a previously established royalty interest. This move marks a strategic financial maneuver for Jaguar Health, aiming to optimize its financial obligations while maintaining operational flexibility.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。